It has been found that the specific inhibitor MCC950 can alleviate diabetic retinopathy by inhibiting NLRP3 inflammasome, but its concentration-dependent efficacy on retinal pathology needs to be explored. The gene discussed is NLRP3; the disease is diabetic retinopathy.